Mucoadhesive Mesoporous Silica Particles as Versatile Carriers for Doxorubicin Delivery in Cancer Therapy.
Mirela-Fernanda ZaltariovBianca-Iulia CiubotaruAlina GhilanDragos PeptanariuMaria IgnatMihail IacobNicoleta VornicuMaria CazacuPublished in: International journal of molecular sciences (2023)
Due to their structural, morphological, and behavioral characteristics (e.g., large volume and adjustable pore size, wide functionalization possibilities, excellent biocompatibility, stability, and controlled biodegradation, the ability to protect cargoes against premature release and unwanted degradation), mesoporous silica particles (MSPs) are emerging as a promising diagnostic and delivery platform with a key role in the development of next-generation theranostics, nanovaccines, and formulations. In this study, MSPs with customized characteristics in-lab prepared were fully characterized and used as carriers for doxorubicin (DOX). The drug loading capacity and the release profile were evaluated in media with different pH values, mimicking the body conditions. The release data were fitted to Higuchi, Korsmeyer-Peppas, and Peppas-Sahlin kinetic models to evaluate the release constant and the mechanism. The in vitro behavior of functionalized silica particles showed an enhanced cytotoxicity on human breast cancer (MCF-7) cells. Bio- and mucoadhesion on different substrates (synthetic cellulose membrane and porcine tissue mucosa)) and antimicrobial activity were successfully assessed, proving the ability of the OH- or the organically modified MSPs to act as antimicrobial and mucoadhesive platforms for drug delivery systems with synergistic effects.
Keyphrases
- cancer therapy
- drug delivery
- endothelial cells
- induced apoptosis
- drug release
- staphylococcus aureus
- high throughput
- emergency department
- electronic health record
- young adults
- big data
- deep learning
- machine learning
- breast cancer cells
- pluripotent stem cells
- aqueous solution
- endoplasmic reticulum stress
- tissue engineering
- cell death
- adverse drug